Abstracts tagged "systemic lupus erythematosus (SLE) and viruses"

Abstract Number: 769 • 2018 ACR/ARHP Annual Meeting
Herpes Zoster in Systemic Lupus Erythematosus: Prevalence and Risk Factors
Hanan Al Rayes¹, Nicole Anderson², Dennisse Bonilla², Jiandong Su² and Zahi Touma², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Herpes zoster (HZ) commonly observed in the elderly and in immune-compromised patients. The prevalence of HZ is 3.6-19.9% in previously reported data. The higher…
Abstract Number: 1093 • 2018 ACR/ARHP Annual Meeting
Serologic Evidence Linking Epstein Barr Virus Reactivation, Heightened Interferon Pathway Activation and Increased Disease Activity in Patients with Systemic Lupus Erythematosus
Rebecca Wood¹, Lauren Guthridge¹, Carla J. Guthridge², Rebecka L. Bourn¹, Hua Chen¹, Wade DeJager¹, Susan R. Macwana¹, Stan Kamp¹, Rufei Lu^1,3, Cristina Arriens¹, Eliza Chakravarty¹, Katherine Thanou¹, Joan T. Merrill¹, Joel M. Guthridge^1,4 and Judith A. James^4,5, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is a clinically heterogeneous disease oftentimes characterized by a waxing and waning course. Mechanisms of SLE flare remain elusive. This study examined relationships…
Abstract Number: 2799 • 2015 ACR/ARHP Annual Meeting
Varicella Zoster Reactivation in Patients with Primary Sjögren’s Syndrome and SLE
Eliza F. Chakarvarty¹, Jacy Odell², Astrid Rasmussen³, Kathy L. Sivils², Joel M. Guthridge² and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, CA, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Increasing data has suggested that individuals with systemic lupus (SLE) are at increased risk of herpes zoster (HZ) reactivation compared to healthy controls and…
Abstract Number: 576 • 2013 ACR/ARHP Annual Meeting
Monitoring Of Opportunistic Virus Infections In Systemic Lupus Erythematosus
Lorenzo Cavagna¹, Sandra Calarota², Eva Scorletti³, Roberto Caporali⁴, Francesca Rovida⁵, Carlomaurizio Montecucco¹ and Fausto Baldanti⁵, ¹Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ²Molecular Virology Unit, Virology and Microbiology Department, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, ³Division of Rheumatology, University and IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, ⁴Division of Rheumatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy, ⁵Molecular Virology Unit, Virology and Microbiology Department, IRCCS Foundation Policlinico S. Matteo,, Pavia, Italy
Background/Purpose: due to disease characteristics and treatment approaches, systemic lupus erythematosus (SLE) patients are at high risk of opportunistic virus infections, as for example Epstein…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].